Title :

Bdr in newly diagnosed patients with wm: final analysis of a phase 2 study after a minimum follow-up of 6 years

Author(s) :

Gavriatopoulou, Maria [Auteur]
Garcia-Sanz, Ramon [Auteur]
Kastritis, Efstathios [Auteur]
Morel, Pierre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Kyrtsonis, Marie-Christine [Auteur]
Michalis, Eurydiki [Auteur]
Kartasis, Zafiris [Auteur]
Leleu, Xavier [Auteur]
Palladini, Giovanni [Auteur]
Tedeschi, Alessandra [Auteur]
Gika, Dimitra [Auteur]
Merlini, Giampaolo [Auteur]
Sonneveld, Pieter [Auteur]
Dimopoulos, Meletios A. [Auteur]

Journal title :

Blood

Abbreviated title :

Blood

Volume number :

129

Pages :

456-459

Publication date :

2017-01-26

ISSN :

0006-4971

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untreated symptomatic patients with Waldenström macroglobulinemia (WM), ...
Show more >In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untreated symptomatic patients with Waldenström macroglobulinemia (WM), most of which were of advanced age and with adverse prognostic factors. BDR consisted of a single 21-day cycle of bortezomib alone (1.3 mg/m222Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T16:54:27Z